Ningbo NewBay Medical Technology Signs an Exclusive License Agreement with Genentech to Develop and Commercialize GDC-0570
Shots:
- Genentech to receive up front- clinical- regulatory and commercial milestone along with royalties on sales of GDC-0570.
- Ningbo NewBay to get an exclusive right to develop & commercialize GDC-0570 and allows it to accelerate the clinical development of investigational therapies
- GDC-0570 is a small molecule Pan-PIM inhibitor- designed to show activity against MM and PC in a preclinical model
Click here to read full press release/ article | Ref: Businesswire | Image: Nature
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
